Literature DB >> 25820354

Clinical outcomes and toxicity after exclusive versus postoperative radiotherapy in supraglottic cancer: new solutions for old problems? The case of stage I and II disease.

Michela Buglione1, Sara Pedretti2, Loredana Costa2, Federica Foscarini2, Marta Maddalo2, Ludovica Pegurri2, Nadia Pasinetti2, Stefano Ciccarelli2, Sandro Tonoli2, Stefano Maria Magrini2.   

Abstract

PURPOSE: To compare acute and late toxicities, survival, and laryngeal preservation after radiotherapy alone (RR) or radiotherapy after partial laryngectomy (PLR) in early supraglottic laryngeal cancer.
MATERIALS AND METHODS: From 1984 to 2012, 172 patients were treated in our department. We analyzed and compared toxicities (CTCAE v 4.0), overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS), local relapse-free survival (LRFS), nodal relapse-free survival (NRFS), metastasis-free survival (MFS), and the number of salvage total laryngectomies.
RESULTS: Patients in the RR group were older (p = 0.05) and had more often comorbidities (p = 0.025); those in the PLR group had mostly T2 disease (p = 0.014). No difference in number of local, nodal, and distant recurrences was found. A higher incidence of late mild dry mouth in patients treated with RR (38 vs. 4 %, p = 0.000) was reported. At univariate analysis, only a younger age, a better performance status, and the absence of comorbidities favorably impacted on OS and DSS. No differences were found in DFS, LRFS, NRFS, MFS, and the number of rescue laryngectomies between the two groups. Younger age and a good performance status persisted as a predictive factor of better survival (OS and DSS) at multivariate analysis.
CONCLUSION: Radical radiotherapy appears to be a viable alternative to conservative surgery, even in elderly patients with poor performance status and comorbidities. Salvage laryngectomy in the RR group was compared favorably with those reported in other conservative surgery series and in the group treated postoperatively of our series.

Entities:  

Keywords:  Laryngeal preservation; Radiotherapy; Supraglottic larynx cancer; Survival; Toxicity

Mesh:

Year:  2015        PMID: 25820354     DOI: 10.1007/s11547-015-0533-1

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  18 in total

1.  Functional outcomes of transoral laser surgery of supraglottic carcinoma compared with a transcervical approach.

Authors:  Rubén Cabanillas; Juan Pablo Rodrigo; Jose Luis Llorente; Vanessa Suárez; Primitivo Ortega; Carlos Suárez
Journal:  Head Neck       Date:  2004-08       Impact factor: 3.147

2.  Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. II. The case of T2N0 disease.

Authors:  Paolo Frata; Enrico Cellai; Stefano M Magrini; Bartolomea Bonetti; Elisabetta Vitali; Sandro Tonoli; Michela Buglione; Fabiola Paiar; Raffaella Barca; Simona Fondelli; Caterina Polli; Lorenzo Livi; Gianpaolo Biti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-08-22       Impact factor: 7.038

3.  Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck.

Authors:  Jay S Cooper; Qiang Zhang; Thomas F Pajak; Arlene A Forastiere; John Jacobs; Scott B Saxman; Julie A Kish; Harold E Kim; Anthony J Cmelak; Marvin Rotman; Robert Lustig; John F Ensley; Wade Thorstad; Christopher J Schultz; Sue S Yom; K Kian Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-06-30       Impact factor: 7.038

4.  Supraglottic laryngeal cancer: analysis of treatment results.

Authors:  Donald G Sessions; Jason Lenox; Gershon J Spector
Journal:  Laryngoscope       Date:  2005-08       Impact factor: 3.325

5.  Carbon dioxide laser microsurgery for early supraglottic carcinoma.

Authors:  P Ambrosch; M Kron; W Steiner
Journal:  Ann Otol Rhinol Laryngol       Date:  1998-08       Impact factor: 1.547

6.  Larynx preservation clinical trial design: key issues and recommendations--a consensus panel summary.

Authors:  Jean-Louis Lefebvre; K Kian Ang
Journal:  Head Neck       Date:  2009-04       Impact factor: 3.147

7.  Oncologic outcomes of transoral laser surgery of supraglottic carcinoma compared with a transcervical approach.

Authors:  Rubén Cabanillas; Juan Pablo Rodrigo; Jose Luis Llorente; Carlos Suárez
Journal:  Head Neck       Date:  2008-06       Impact factor: 3.147

8.  Endoscopic horizontal partial laryngectomy by CO(2) laser in the management of supraglottic squamous cell carcinoma.

Authors:  Francesco Bussu; Giovanni Almadori; Eugenio De Corso; Davide Rizzo; Mario Rigante; Claudio Parrilla; Vincenzo Valentini; Gaetano Paludetti
Journal:  Head Neck       Date:  2009-09       Impact factor: 3.147

9.  Prognostic significance of nodal metastasis in advanced tumors of the larynx and hypopharynx.

Authors:  Ricardo Barroso Ribeiro; Eduardo Ribeiro Breda; Eurico Fernandes Monteiro
Journal:  Acta Otorrinolaringol Esp       Date:  2012-05-11

10.  Supraglottic laryngectomy with or without postoperative radiotherapy in supraglottic carcinomas.

Authors:  C Suárez; J P Rodrigo; J Herranz; J L Llorente; J A Martínez
Journal:  Ann Otol Rhinol Laryngol       Date:  1995-05       Impact factor: 1.547

View more
  2 in total

1.  When is definitive radiotherapy the preferred treatment for head and neck squamous cell carcinoma?

Authors:  William M Mendenhall; Primož Strojan; Avraham Eisbruch; Robert Smee; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-30       Impact factor: 2.503

2.  Clinical outcomes and toxicity after exclusive versus postoperative radiotherapy in supraglottic cancer: new solutions for old problems? The case of stage III and IV disease.

Authors:  Loredana Costa; Sara Pedretti; Federica Foscarini; Marta Maddalo; Ludovica Pegurri; Nadia Pasinetti; Roberta Cavagnini; Stefano Ciccarelli; Sandro Tonoli; Stefano Maria Magrini; Michela Buglione
Journal:  Radiol Med       Date:  2015-08-01       Impact factor: 3.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.